Study Using Oxford BioDynamics' EpiSwitch Enrols First Patient

(Alliance News) - Oxford BioDynamics PLC said Friday Mitsubishi Tanabe Pharma America Inc, a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corp, has enrolled its first patient in a trial measuring biomarkers in people with amyotrophic lateral sclerosis.

As part of the trial, Mitsubishi Tanabe Pharma America is using Oxford BioDynamics's technology platform EpiSwitch to assess the rate of ALS disease progression, using "highly novel" epigenetic biomarkers for patients who have begun treatment of Radicava.

"We are honored to be working with so many esteemed collaborators on this novel study and excited to have reached this milestone of enrolling the first patient," said Stephen Apple, Senior Medical Director at Mitsubishi Tanabe Pharma America. "This research has great potential to provide a deeper understanding of the biological effects of Radicava."

The study includes assessments of biomarkers for oxidative stress, inflammation, neuronal and muscle injury. Biomarkers will be measured prior to initiating treatment, at the start of treatment, and at pre-specified time points throughout the 24-week study period. Interim results are expected in 2020.

Shares in Oxford BioDynamics were untraded in London on Friday but last closed at 95.50 pence each.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Oxford Biodyn